Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
101.21
+2.70 (2.74%)
At close: Apr 28, 2026, 4:00 PM EDT
103.23
+2.02 (2.00%)
After-hours: Apr 28, 2026, 5:32 PM EDT
Protagonist Therapeutics Employees
Protagonist Therapeutics had 132 employees as of December 31, 2025. The number of employees increased by 6 or 4.76% compared to the previous year.
Employees
132
Change (1Y)
6
Growth (1Y)
4.76%
Revenue / Employee
$348,606
Profits / Employee
-$985,977
Market Cap
6.46B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 362 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Arcellx | 209 |
| Celcuity | 155 |
| Centessa Pharmaceuticals | 118 |
| Erasca | 103 |
PTGX News
- 13 hours ago - Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration - Accesswire
- 12 days ago - Protagonist Therapeutics Reports Granting of Inducement Awards - Accesswire
- 4 weeks ago - Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Accesswire
- 5 weeks ago - Protagonist Therapeutics Transcript: FDA announcement - Transcripts
- 5 weeks ago - Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - Accesswire
- 6 weeks ago - Protagonist Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Protagonist Therapeutics Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Protagonist Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts